265 related articles for article (PubMed ID: 38249515)
1. Chemoprevention of neuroblastoma: progress and promise beyond uncertainties.
Aravindan N; Natarajan M; Somasundaram DB; Aravindan S
J Cancer Metastasis Treat; 2023; 9():. PubMed ID: 38249515
[TBL] [Abstract][Full Text] [Related]
2. Difluoromethylornithine (DFMO) and Neuroblastoma: A Review.
Tangella AV; Gajre AS; Chirumamilla PC; Rathhan PV
Cureus; 2023 Apr; 15(4):e37680. PubMed ID: 37206500
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
Kraveka JM; Lewis EC; Bergendahl G; Ferguson W; Oesterheld J; Kim E; Nagulapally AB; Dykema KJ; Brown VI; Roberts WD; Mitchell D; Eslin D; Hanson D; Isakoff MS; Wada RK; Harrod VL; Rawwas J; Hanna G; Hendricks WPD; Byron SA; Snuderl M; Serrano J; Trent JM; Saulnier Sholler GL
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1616. PubMed ID: 35355452
[TBL] [Abstract][Full Text] [Related]
4. New agents for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet RA; Doody LA; Malone WF; Hawk ET; Sigman CC
J Cell Biochem Suppl; 1996; 26():1-28. PubMed ID: 9154166
[TBL] [Abstract][Full Text] [Related]
5. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
6. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.
Lewis EC; Kraveka JM; Ferguson W; Eslin D; Brown VI; Bergendahl G; Roberts W; Wada RK; Oesterheld J; Mitchell D; Foley J; Zage P; Rawwas J; Rich M; Lorenzi E; Broglio K; Berry D; Saulnier Sholler GL
Int J Cancer; 2020 Dec; 147(11):3152-3159. PubMed ID: 32391579
[TBL] [Abstract][Full Text] [Related]
7. Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P; Cañete A; Castel V
Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
[TBL] [Abstract][Full Text] [Related]
8. Cancer Chemoprevention: A Strategic Approach Using Phytochemicals.
G MS; Swetha M; Keerthana CK; Rayginia TP; Anto RJ
Front Pharmacol; 2021; 12():809308. PubMed ID: 35095521
[TBL] [Abstract][Full Text] [Related]
9. Progress in cancer chemoprevention.
Kelloff GJ; Crowell JA; Steele VE; Lubet RA; Boone CW; Malone WA; Hawk ET; Lieberman R; Lawrence JA; Kopelovich L; Ali I; Viner JL; Sigman CC
Ann N Y Acad Sci; 1999; 889():1-13. PubMed ID: 10668477
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of prostate cancer: concepts and strategies.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovitch L; Malone WA; Crowell JA; Sigman CC
Eur Urol; 1999; 35(5-6):342-50. PubMed ID: 10325487
[TBL] [Abstract][Full Text] [Related]
11. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
12. [High-risk neuroblastoma treatment strategy: The experience of the SIOPEN group].
Valteau-Couanet D; Schleiermacher G; Sarnacki S; Pasqualini C
Bull Cancer; 2018 Oct; 105(10):918-924. PubMed ID: 30290975
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.
Makena MR; Cho HE; Nguyen TH; Koneru B; Verlekar DU; Hindle A; Kang MH; Reynolds CP
Pediatr Blood Cancer; 2018 Dec; 65(12):e27447. PubMed ID: 30251395
[TBL] [Abstract][Full Text] [Related]
14. Emerging and investigational therapies for neuroblastoma.
Applebaum MA; Desai AV; Glade Bender JL; Cohn SL
Expert Opin Orphan Drugs; 2017; 5(4):355-368. PubMed ID: 29062613
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic targets for neuroblastoma.
Aravindan N; Herman T; Aravindan S
Expert Opin Ther Targets; 2020 Sep; 24(9):899-914. PubMed ID: 33021426
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
17. Advances in pharmacotherapy for neuroblastoma.
Pezeshki PS; Moeinafshar A; Ghaemdoust F; Razi S; Keshavarz-Fathi M; Rezaei N
Expert Opin Pharmacother; 2021 Dec; 22(17):2383-2404. PubMed ID: 34254549
[TBL] [Abstract][Full Text] [Related]
18. Immune therapies for neuroblastoma.
Navid F; Armstrong M; Barfield RC
Cancer Biol Ther; 2009 May; 8(10):874-82. PubMed ID: 19342881
[TBL] [Abstract][Full Text] [Related]
19. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.
Amoroso L; Haupt R; Garaventa A; Ponzoni M
Expert Opin Investig Drugs; 2017 Nov; 26(11):1281-1293. PubMed ID: 28906153
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
